共查询到20条相似文献,搜索用时 31 毫秒
1.
Optimization of the preparation of fluorine‐18‐labeled steroid receptor ligands 16alpha‐[18F]fluoroestradiol (FES), [18F]fluoro furanyl norprogesterone (FFNP), and 16beta‐[18F]fluoro‐5alpha‐dihydrotestosterone (FDHT) as radiopharmaceuticals
下载免费PDF全文
![点击此处可从《Journal of labelled compounds & radiopharmaceuticals》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Dong Zhou Mai Lin Norio Yasui Mohammed H. Al‐Qahtani Carmen S. Dence Sally Schwarz John A. Katzenellenbogen 《Journal of labelled compounds & radiopharmaceuticals》2014,57(5):371-377
Fluorine‐18‐labeled steroid receptor tracers, 16α‐[18F]fluoroestradiol (FES), [18F]fluoro furanyl norprogesterone (FFNP), and 16β‐[18F]fluoro‐5α‐dihydrotestosterone (FDHT), are important imaging tools for studies of breast and prostate cancers using positron emission tomography (PET). The automated production of these ligands with high specific activity (SA) as radiopharmaceuticals requires modification and optimization of the currently reported methods. [18F]FES with high SA was synthesized in over 60% radiochemical yield (RCY) at the end of synthesis (EOS) using a small amount of precursor (1) (as low as 0.3 mg) and 1 M H2SO4 for deprotection of the intermediate (2). [18F]FFNP was synthesized in up to 77% RCY at EOS using the triflate precursor (4) at room temperature or in 25% RCY using the mesylate precursor (6) at 65°C. Both methods are highly reproducible and afford high SA. [18F]FDHT was synthesized by radiofluoride incorporation at room temperature, reduction with NaBH4, and deprotection with HCl/acetone, giving [18F]FDHT in up to 75% yield (RCY). All of these methods can be easily translated to automated production. The information provided here will aid in the development of automated production of these steroid receptor tracers with high or improved yields, optimal SA, and ease of processing for research and clinical use. Copyright © 2014 John Wiley & Sons, Ltd. 相似文献
2.
《Journal of labelled compounds & radiopharmaceuticals》2017,60(1):36-48
Cyclic nucleotide phosphodiesterase 10A (PDE10A) regulates the level of the second messengers cAMP and cGMP in particular in brain regions assumed to be associated with neurodegenerative and psychiatric diseases. A better understanding of the pathophysiological role of the expression of PDE10A could be obtained by quantitative imaging of the enzyme by positron emission tomography (PET). Thus, in this study we developed, radiolabeled, and evaluated a new PDE10A radioligand, 8‐bromo‐1‐(6‐[18F]fluoropyridin‐3‐yl)‐3,4‐dimethylimidazo[1,5‐a ]quinoxaline ([18F] AQ28A ). [18F] AQ28A was radiolabeled by both nucleophilic bromo‐to‐fluoro or nitro‐to‐fluoro exchange using K[18F]F‐K2.2.2‐carbonate complex with different yields. Using the superior nitro precursor, we developed an automated synthesis on a Tracerlab FX F‐N module and obtained [18F] AQ28A with high radiochemical yields (33 ± 6%) and specific activities (96‐145 GBq·μmol−1) for further evaluation. Initially, we investigated the binding of [18F] AQ28A to the brain of different species by autoradiography and observed the highest density of binding sites in striatum, the brain region with the highest PDE10A expression. Subsequent dynamic PET studies in mice revealed a region‐specific accumulation of [18F] AQ28A in this region, which could be blocked by preinjection of the selective PDE10A ligand MP‐10. In conclusion, the data suggest [18F] AQ28A is a suitable candidate for imaging of PDE10A in rodent brain by PET. 相似文献
3.
Norihiro Harada Shingo Nishiyama Masakatsu Kanazawa Hideo Tsukada 《Journal of labelled compounds & radiopharmaceuticals》2013,56(11):553-561
We developed three novel positron‐emission tomography (PET) probes, 2‐tert‐butyl‐4‐chloro‐5‐{6‐[2‐(2[18F]fluoroethoxy)‐ethoxy]‐pyridin‐3‐ylmethoxy}‐2H‐pyridazin‐3‐one ([18F]BCPP‐EF), 2‐tert‐butyl‐4‐chloro‐5‐[6‐(4‐[18F]fluorobutoxy)‐pyridin‐3‐ylmethoxy]‐2H‐pyridazin‐3‐one ([18F]BCPP‐BF), and 2‐tert‐butyl‐4‐chloro‐5‐{6‐[2‐(2‐[11C]methoxy‐ethoxy)‐ethoxy]‐pyridin‐3‐ylmethoxy}‐2H‐pyridazin‐3‐one ([11C]BCPP‐EM), for quantitative imaging of mitochondrial complex 1 (MC‐1) activity in vivo. These three PET probes were successfully labeled by nucleophilic [18F]fluorination or by [11C]methylation of their corresponding precursor with sufficient radioactivity yield, good radiochemical purity, and sufficiently high specific radioactivity for PET measurement. The specificity of these probes for binding to MC‐1 was assessed with rotenone, a specific MC‐1 inhibitor, by a rat brain slice imaging method in vitro. Rat whole‐body imaging by small‐animal PET demonstrated that all probes showed high uptake levels in the brain as well as in the heart sufficient to image them clearly. The rank order of uptake levels in the brain and the heart just after injection was as follows: high in [18F]BCPP‐BF, intermediate in [11C]BCPP‐EM, and low in [18F]BCPP‐EF. The kinetics of [18F]BCPP‐EF and [11C]BCPP‐EM provided a reversible binding pattern, whereas [18F]BCPP‐BF showed nonreversible accumulation‐type kinetics in the brain and heart. Metabolite analyses indicated that these three compounds were rapidly metabolized in the plasma but relatively stable in the rat brain up to 60 min post‐injection. The present study demonstrated that [18F]BCPP‐EF could be a useful PET probe for quantitative imaging of MC‐1 activity in the living brain by PET. 相似文献
4.
《Journal of labelled compounds & radiopharmaceuticals》2003,46(13):1229-1240
Recently, two fluorine‐18 labelled derivatives of flumazenil were described: 5‐(2′‐[18F]fluoroethyl)‐5‐desmethylflumazenil (ethyl 8‐fluoro‐5‐[18F]fluoroethyl‐6‐oxo‐5,6‐dihydro‐4H‐benzo‐[f]imidazo[1,5‐a] [1,4]diazepine‐3‐carboxylate; [18F]FEFMZ) and 3‐(2′‐[18F]fluoro)‐flumazenil (2′‐[18F]fluoroethyl 8‐fluoro‐5‐methyl‐6‐oxo‐5,6‐dihydro‐4H‐benzo‐[f]imidazo[1,5‐a]‐[1,4]diazepine‐3‐carbo‐ xylate; [18F]FFMZ). Since the biodistribution data of the latter were superior to those of the former we developed a synthetic approach for [18F]FFMZ starting from a commercially available precursor, thereby obviating the need to prepare a precursor by ourselves. The following two‐step procedure was developed: First, [18F]fluoride was reacted with 2‐bromoethyl triflate using the kryptofix/acetonitrile method to yield 2‐bromo‐[18F]fluoroethane ([18F]BFE). In the second step, distilled [18F]BFE was reacted with the tetrabutylammonium salt of 3‐desethylflumazenil (8‐fluoro‐5‐methyl‐6‐oxo‐5,6‐dihydro‐4H‐benzo‐[f]imidazo[1,5‐a] [1,4]diazepine‐3‐carboxylic acid) to yield [18F]FFMZ. The synthesis of [18F]FFMZ allows for the production of up to 7 GBq of this PET‐tracer, enough to serve several patients. [18F]FFMZ synthesis was completed in less than 80 min and the radiochemical purity exceeded 98%. Copyright © 2003 John Wiley & Sons, Ltd. 相似文献
5.
Hao Xiao Seok Rye Choi Ruiyue Zhao Karl Ploessl David Alexoff Lin Zhu Zhihao Zha Hank F. Kung 《ACS medicinal chemistry letters》2021,12(7):1086
[18F]AV-45 (florbetapir f18, Amyvid) is an FDA-approved PET imaging agent targeting Aβ plaques in the brain for diagnosis of Alzheimer’s disease (AD). Its metabolites led to a high background in the brain and large bone uptake of [18F]F–, produced from dealkylation of the PEG chain. To slow down the in vivo metabolism, we report the design, synthesis, and evaluation of a highly deuterated derivative, [18F]D15FSP, and compared it with N-methyl-deuterated [18F]D3FSP and nondeuterated [18F]AV-45. D15FSP displayed excellent binding affinity (Ki = 7.52 nM) to Aβ aggregates. In vitro autoradiography of [18F]D15FSP, [18F]D3FSP, and [18F]AV-45 showed excellent binding to Aβ plaques in human AD brain sections. Biodistribution studies displayed lower bone uptake at 120 min for [18F]D15FSP compared to that for [18F]D3FSP and [18F]AV-45 (1.44 vs 4.23 and 4.03%ID/g, respectively). As the highly deuterated [18F]D15FSP displayed excellent Aβ binding affinity, high initial brain penetration, and lower bone retention, it might be suitable for PET imaging in detecting Aβ plaques. 相似文献
6.
《Journal of labelled compounds & radiopharmaceuticals》2002,45(13):1103-1113
The scope of the nucleophilic aromatic ortho‐fluorinations from the corresponding ortho‐halonitrobenzene precursors (halo‐to‐fluoro substitutions) with no‐carrier‐added [18F]fluoride ion as its activated K[18F]F–K222 complex has been evaluated via the radiosynthesis of ortho‐[18F]fluoronitrobenzene, chosen as a model reaction. The parameters studied include the influence of the leaving group in the ortho position of the phenyl ring (–Cl, –Br, –l), the quantity of precursor used, the type of activation (conventional heating or microwave irradiations), the solvent, the temperature and the reaction time. The iodo‐precursor was completely unreactive and the bromo‐precursor gave only low incorporation (<10%) in the optimal conditions used (conventional heating at 145°C or microwave activation, 100 W for 120 s). Only the chloro‐precursor was found reactive in the conditions described above and up to 70% yield was observed for the formation of ortho‐[18F]fluoronitrobenzene ([18F]‐ 1 ). In all the experiments, the unwanted ortho‐[18F]fluoro‐halobenzenes, potentially resulting from the nitro‐to‐fluoro substitution, could not be detected. These results will be applied for the radiosynthesis of 5‐[18F]fluoro‐6‐nitroquipazine, a potent radioligand for the imaging of the serotonin transporter with PET. Copyright © 2002 John Wiley & Sons, Ltd. 相似文献
7.
Kongzhen Hu Junqi Li Lijuan Wang Yong Huang Li Li Shimin Ye Yanjiang Han Shun Huang Hubing Wu Jin Su Ganghua Tang 《药学学报(英文版)》2022,12(2):867-875
In recent years, fibroblast activation protein (FAP) has emerged as an attractive target for the diagnosis and radiotherapy of cancers using FAP-specific radioligands. Herein, we aimed to design a novel 18F-labeled FAP tracer ([18F]AlF-P-FAPI) for FAP imaging and evaluated its potential for clinical application. The [18F]AlF-P-FAPI novel tracer was prepared in an automated manner within 42 min with a non-decay corrected radiochemical yield of 32 ± 6% (n = 8). Among A549-FAP cells, [18F]AlF-P-FAPI demonstrated specific uptake, rapid internalization, and low cellular efflux. Compared to the patent tracer [18F]FAPI-42, [18F]AlF-P-FAPI exhibited lower levels of cellular efflux in the A549-FAP cells and higher stability in vivo. Micro-PET imaging in the A549-FAP tumor model indicated higher specific tumor uptake of [18F]AlF-P-FAPI (7.0 ± 1.0% ID/g) compared to patent tracers [18F]FAPI-42 (3.2 ± 0.6% ID/g) and [68Ga]Ga-FAPI-04 (2.7 ± 0.5% ID/g). Furthermore, in an initial diagnostic application in a patient with nasopharyngeal cancer, [18F]AlF-P-FAPI and [18F]FDG PET/CT showed comparable results for both primary tumors and lymph node metastases. These results suggest that [18F]AlF-P-FAPI can be conveniently prepared, with promising characteristics in the preclinical evaluation. The feasibility of FAP imaging was demonstrated using PET studies. 相似文献
8.
Tim A. D. Smith 《Journal of labelled compounds & radiopharmaceuticals》2012,55(8):281-288
[18F]Fluorination is usually carried out by nucleophilic substitution reactions entailing the use of stringent conditions. A number of novel techniques including silicon and boron‐based fluoride acceptor molecules, [18F]fluoro‐2‐deoxy‐ d ‐glucose and chelation of the Al18F complex have been employed recently to achieve [18F]radiolabelling of macromolecules. These approaches are reviewed herein. Copyright © 2012 John Wiley & Sons, Ltd. 相似文献
9.
Scott M. Apana Robert J. Griffin Nathan A. Koonce Jessica S. Webber Ruud P. M. Dings Kevin H. Mayo Marc S. Berridge 《Journal of labelled compounds & radiopharmaceuticals》2011,54(11):708-713
Anginex is a 33‐residue peptide that has been previously demonstrated to possess antiangiogenic properties. To provide a tool to evaluate the regional biodistribution and pharmacokinetics of anginex, and possibly to provide a useful angiogenesis‐targeted radiotracer, we have radiolabeled anginex with fluorine‐18. High specific activity [18F]fluorobenzaldehyde (1.5–4.8 TBq (40–130 Ci)/µmol) was used to label anginex via reductive amination in 76% yield. The effective specific activity of the product was lower because unlabeled anginex was not separated. However, the high specific activity labeling reagent increased the labeling yield and reduced the amount of anginex required for labeling. Regional pharmacokinetics were measured by PET scanning in mice, demonstrating tumor uptake and low background, with up to 30% of total injected dose localized in some tumors. Copyright © 2011 John Wiley & Sons, Ltd. 相似文献
10.
Thomas A. Singleton Hussein Bdair Justin J. Bailey Sangho Choi Arturo Aliaga Pedro Rosa-Neto Ralf Schirrmacher Vadim Bernard-Gauthier Alexey Kostikov 《Journal of labelled compounds & radiopharmaceuticals》2020,63(3):144-150
Herein we report an efficient radiolabeling of a 18F-fluorinated derivative of dual inhibitor GW2580, with its subsequent evaluation as a positron emission tomography (PET) tracer candidate for imaging of two neuroreceptor targets implicated in the pathophysiology of neurodegeneration: tropomyosin receptor kinases (TrkB/C) and colony stimulating factor receptor (CSF-1R). [18F]FOMPyD was synthesized from a boronic acid pinacolate precursor via copper-mediated 18F-fluorination concerted with thermal deprotection of the four Boc groups on a diaminopyrimidine moiety in an 8.7±2.8% radiochemical yield, a radiochemical purity >99%, and an effective molar activity of 187±93 GBq/μmol. [18F]FOMPyD showed moderate brain permeability in wild-type rats (SUVmax = 0.75) and a slow washout rate. The brain uptake was partially reduced (ΔAUC40–90 = 11.6%) by administration of the nonradioactive FOMPyD (up to 30 μg/kg). In autoradiography, [18F]FOMPyD exhibits ubiquitous distribution in rat and human brain tissues with relatively high nonspecific binding revealed by self-blocking experiment. The binding was blocked by TrkB/C inhibitors, but not with a CSF-1R inhibitor, suggesting selective binding to the former receptor. Although an unfavorable pharmacokinetic profile will likely preclude application of [18F]FOMPyD as a PET tracer for brain imaging, the concomitant one-pot copper-mediated 18F-fluorination/Boc-deprotection is a practical technique for the automated radiosynthesis of acid-sensitive PET tracers. 相似文献
11.
《Drug metabolism and pharmacokinetics》2019,34(5):317-324
Quantitative evaluations of the functions of uptake and efflux transporters directly in vivo is desired to understand an efficient hepatobiliary transport of substrate drugs. Pitavastatin is a substrate of organic anion transporting polypeptides (OATPs) and canalicular efflux transporters; thus, it can be a suitable probe for positron-emission tomography (PET) imaging of hepatic transporter functions. To characterize the performance of [18F]PTV-F1, an analogue of pitavastatin, we investigated the impact of rifampicin (a typical OATP inhibitor) coadministration or Bcrp (breast cancer resistance protein) knockout on [18F]PTV-F1 hepatic uptake and efflux in rats by PET imaging. After intravenous administration, [18F]PTV-F1 selectively accumulated in the liver, and the radioactivity detected in plasma, liver, and bile mainly derived from the parent PTV-F1 during the PET study (∼40 min). Coadministration of rifampicin largely decreased the hepatic uptake of [18F]PTV-F1 by 73%. Because of its lower clearance in rats, [18F]PTV-F1 is more sensitive for monitoring changes in hepatic OATP1B function that other previously reported OATP1B PET probes. Rifampicin coadministration also significantly decreased the biliary excretion of radioactivity by 65%. Bcrp knockout did not show a significant impact on its biliary excretion.[18F]PTV-F1 enables quantitative analysis of the hepatobiliary transport system for organic anions. 相似文献
12.
It is widely accepted that uptake and efflux transporters on clearance organs play crucial roles in drug disposition. Although in vitro transporter assay system can identify the intrinsic properties of the target transporters, it is not so easy to precisely predict in vivo pharmacokinetic parameters from in vitro data. Positron emission tomography (PET) imaging is a useful tool to directly assess the activity of drug transporters in humans. We recently developed a practical synthetic method for fluorine-18-labeled pitavastatin ([18F]PTV) as a PET probe for quantitative evaluation of hepatobiliary transport. In the present study, we conducted clinical PET imaging with [18F]PTV and compared the pharmacokinetic properties of the probe for healthy subjects with or without rifampicin pretreatment. Rifampicin pretreatment significantly suppressed the hepatic maximum concentration and biliary excretion of the probe to 52% and 34% of the control values, respectively. Rifampicin treatment markedly decreased hepatic uptake clearance (21% of the control), and moderately canalicular efflux clearance with regard to hepatic concentration (52% of the control). These results demonstrate that [18F]PTV is a useful probe for clinical investigation of the activities of hepatobiliary uptake/efflux transporters in humans. 相似文献
13.
《Journal of labelled compounds & radiopharmaceuticals》2003,46(6):587-598
[18F]Fluoroethyl bromide ([18F]FEtBr) is a useful synthetic precursor to synthesize 18F‐labeled compounds. However, the lower reactivity of [18F]FEtBr with amine, phenol and amide functional groups than that of [11C]CH3I partly limits its wide application in the synthesis of [18F]fluoroethylated compounds. The aim of this study was to increase the reactivity of [18F]FEtBr with various nucleophilic substrates for PET tracers containing amine, phenol and amide moieties. The present strategies included (1) adding NaI into the reaction mixture of [18F]FEtBr and substrate, where [18F]FEtI is reversibly formed and becomes more reactive; (2) converting [18F]FEtBr into much more reactive [18F]FEtOTf, similar to conversion of [11C]CH3I into [11C]CH3OTf. By these efforts, the [18F]fluoroethylation efficiency of various substrates containing amine, phenol and amide groups with [18F]FEtBr/NaI and [18F]FEtOTf was significantly improved, compared with the corresponding reaction efficiency with [18F]FEtBr. Copyright © 2003 John Wiley & Sons, Ltd. 相似文献
14.
Qing Xu Chen Zhu Yuping Xu Donghui Pan Ping Liu Runlin Yang 《Journal of drug targeting》2015,23(9):813-820
Background: High expression of glucagon-like peptide-1 receptor (GLP-1R) in insulinoma supplies a potential drug target for tumor imaging. Exendin-4 can specifically bind to GLP-1R as an agonist and its analogs are extensively used in receptor imaging studies.Purpose: A new GLP-1R imaging agent, [18F]AlF-NOTA-MAL-Cys39-exendin-4, was designed and prepared for insulinoma imaging.Methods: Cys39-exendin-4 was conjugated with NOTA-MAL, then the compound was radiolabeled with [18F]AlF complex to obtained [18F]AlF-NOTA-MAL-Cys39-exendin-4. The tumor-targeting characters of the tracer were evaluated in INS-1 cells and BALB/c nude mice models.Results: [18F]AlF-NOTA-MAL-Cys39-exendin-4 can be efficiently produced with a yield of 17.5?±?3.2% (non-decay corrected) and radiochemical purity of >95%. The IC50 value of displacement [18F]AlF-NOTA-MAL-Cys39-exendin-4 with Cys39-exendin-4 was 13.52?±?1.36?nM. PET images showed excellent tumor visualization with high uptake (9.15?±?1.6%ID/g at 30?min and 7.74?±?0.87%ID/g at 60?min). The tumor to muscle, pancreas and liver ratios were 63.25, 3.85 and 7.29 at 60?min after injection. GLP-1R binding specificity was demonstrated by co-injection with an excess of unlabeled Cys39-exendin-4 and the tumor uptake was found to be reduced significantly.Conclusion: [18F]AlF-NOTA-MAL-Cys39-exendin-4 shows favorable characteristics for insulinoma imaging and may be translated to clinical studies. 相似文献
15.
Yoo J Dence CS Sharp TL Katzenellenbogen JA Welch MJ 《Journal of medicinal chemistry》2005,48(20):6366-6378
Estrogen receptor beta (ERbeta), a less active ER subtype that appears to have a restraining effect on the more active ERalpha, could be a factor that determines the level of estrogen action in certain estrogen target tissues. ERbeta is found in breast cancer, and its levels relative to ERalpha decline with disease progression. Thus, the independent quantification of ERalpha and ERbeta levels in breast cancer by imaging might be predictive of responses to different hormone therapies. To develop an imaging agent for ERbeta, we synthesized a fluoroethyl analogue of DPN (2,3-bis(4-hydroxyphenyl)propanonitrile), a known ERbeta-selective ligand. This analogue, FEDPN (5-fluoro-(2R,3S)-2,3-bis(4-hydroxyphenyl)pentanenitrile), has an 8.3-fold absolute affinity preference for ERbeta. [18F]Fluoride-labeled FEDPN was prepared from a toluenesulfonate precursor, which provided [18F]FEDPN with a specific activity greater than 3100 Ci/mmol after HPLC purification. Biodistribution studies in immature female rats using estradiol as a blocking agent revealed specific uptake of [18F]FEDPN in the uterus and ovaries. Experiments using ERalpha- and ERbeta-knockout mice demonstrated the expected ERalpha-subtype dependence in the tissue uptake of the known 16alpha-[18F]fluoro-17beta-estradiol ([18F]FES), which has a 6.3-fold preference for ERalpha. The tissue uptake of [18F]FEDPN in the ER knockout mice showed some evidence of mediation by ERbeta, but the levels of specific uptake of this agent were relatively modest. Based on our results, imaging of ERalpha can be done effectively with [18F]FES, but imaging of ERbeta will likely require agents with more optimized ERbeta binding affinity and selectivity than [18F]FEDNP. 相似文献
16.
Synthesis and preliminary evaluation of a 18F‐labeled ethisterone derivative [18F]EAEF for progesterone receptor targeting
下载免费PDF全文
![点击此处可从《Chemical biology & drug design》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Xiaowei Wu Linyi You Deliang Zhang Mengna Gao Zijing Li Duo Xu Pu Zhang Lumei Huang Rongqiang Zhuang Hua Wu Xianzhong Zhang 《Chemical biology & drug design》2017,89(4):559-565
To develop a novel progesterone receptor‐targeting probe for positron emission tomography imaging, an ethisterone derivative [18F]EAEF was designed and prepared in high decay‐corrected radiochemical yield (30–35%) with good radiochemical purity (>98%). [18F]EAEF is a lipophilic tracer (logP = 0.53 ± 0.06) with very good stability in saline and serum. In the biodistribution study, high radioactivity accumulation of [18F]EAEF were found in uterus (5.73 ± 1.83% ID/g) and ovary (4.05 ± 0.73% ID/g) at 2 hr postinjection (p.i.), which have high progesterone receptor expression after treated with estradiol, while the muscle background has very low uptake (0.50 ± 0.17% ID/g). For positron emission tomography imaging, [18F]EAEF showed high uptake in progesterone receptor‐positive MCF‐7 tumor (3.15 ± 0.07% ID/g at 2 hr p.i.) with good tumor to muscle ratio (2.90), and obvious lower tumor uptakes were observed in MCF‐7 with EAEF blocking (1.84 ± 0.05% ID/g at 2 hr p.i.) or in progesterone receptor‐negative MDA‐MB‐231 tumor (1.80 ± 0.03% ID/g at 2 hr p.i.). Based on the good stability and specificity of [18F]EAEF, it may be a good candidate for imaging progesterone receptor and worth further investigation. 相似文献
17.
Friederike Beyerlein Markus Piel Sabine Höhnemann Frank Rösch 《Journal of labelled compounds & radiopharmaceuticals》2013,56(7):360-363
Automated synthetic procedures of [18F]fluoro‐[di‐deutero]methyl tosylate on a GE TRACERlab FX F‐N module and a non‐commercial synthesis module have been developed. The syntheses included azeotropic drying of the [18F]fluoride, nucleophilic 18F‐fluorination of bis(tosyloxy)‐[di‐deutero]methane, HPLC purification and subsequent formulation of the synthesized [18F]fluoro‐[di‐deutero]methyl tosylate (d2‐[18F]FMT) in organic solvents. Automation shortened the total synthesis time to 50 min, resulting in an average radiochemical yield of about 50% and high radiochemical purity (>98%). The possible application of this procedure to commercially available synthesis modules might be of significance for the production of deuterated 18F‐fluoromethylated imaging probes in the future. Copyright © 2013 John Wiley & Sons, Ltd. 相似文献
18.
Robert Hopewell Karen Ross Alexey Kostikov Tharick A. Pascoal Thais Alberti Monica Lacatus‐Samoila Jean‐Paul Soucy Idriss Bennacef Eliane Kobayashi Min Su Kang Pedro Rosa‐Neto Gassan Massarweh 《Journal of labelled compounds & radiopharmaceuticals》2019,62(2):109-114
[18F]MK‐6240 (6‐(fluoro)‐3‐(1H‐pyrrolo[2,3‐c]pyridin‐1‐yl)isoquinolin‐5‐amine) is a highly selective PET radiotracer for the in vivo imaging of neurofibrillary tangles (NFTs). [18F]MK‐6240 was synthesized in one step from its bis‐Boc protected precursor N‐[(tert‐butoxy)carbonyl]‐N‐(6‐nitro‐3‐[1H‐pyrrolo[2,3‐c]pyridin‐1‐yl]isoquinolin‐5‐yl) carbamate in DMSO using [18F] fluoride with TEA HCO3 with step‐wise heating up to 150°C, resulting in an isolated radiochemical yield of 9.8% ± 1.8% (n = 3) calculated from the end of bombardment (5.2% ± 1.0% calculated from the end of synthesis). This new synthetic approach eliminates the acidic deprotection of the bis‐Boc 18F‐labeled intermediate, which reduces the number of operations necessary for the synthesis as well as losses, which occur during deprotection and neutralization of the crude product mixture prior to the HPLC purification. The synthesis was performed automatically with a single‐use cassette on an IBA Synthera+ synthesis module. This synthesis method affords the radioligand with a reliable radiochemical yield, high radiochemical purity, and a high molar activity. [18F]MK‐6240 synthesized with this method has been regularly (n > 60) used in our ongoing human and animal PET imaging studies. 相似文献
19.
Thu Hang Lai Barbara Wenzel Rareş-Petru Moldovan Peter Brust Klaus Kopka Rodrigo Teodoro 《Journal of labelled compounds & radiopharmaceuticals》2022,65(6):162-166
[18F] FLUDA is a selective radiotracer for in vivo imaging of the adenosine A2A receptor (A2AR) by positron emission tomography (PET). Promising preclinical results obtained by neuroimaging of mice and piglets suggest the translation of [18F] FLUDA to human PET studies. Thus, we report herein a remotely controlled automated radiosynthesis of [18F] FLUDA using a GE TRACERlab FX2 N radiosynthesizer. The radiotracer was obtained by a one-pot two-step radiofluorination procedure with a radiochemical yield of 9±1%, a radiochemical purity of ≥99%, and molar activities in the range of 69–333 GBq/μmol at the end of synthesis within a total synthesis time of approx. 95 min (n = 16). Altogether, we successfully established a reliable and reproducible procedure for the automated production of [18F] FLUDA. 相似文献
20.
Ken Kersemans John Mertens Vicky Caveliers 《Journal of labelled compounds & radiopharmaceuticals》2010,53(2):58-62
Currently there is still a need for more potent amino acid analogues as tumour imaging agents for peripheral tumour imaging with PET as it was recently reported that the success of O‐(2′‐[18F]fluoroethyl)‐L ‐tyrosine ([18F]FET) is limited to brain, head and neck tumours. As the earlier described 2‐Amino‐3‐(2‐[18F]fluoromethyl‐phenyl)‐propionic acid (2‐[18F]FMP) suffered from intramolecular‐catalysed defluorination, we synthesized 2‐Amino‐3‐(4‐[18F]fluoromethyl‐phenyl)‐propionic acid (4‐[18F]FMP) as an alternative for tumour imaging with PET. Radiosynthesis of 4‐[18F]FMP, based on Br for [18F] aliphatic nucleophilic exchange, was performed with a customized modular Scintomics automatic synthesis hotboxthree system in a high overall yield of 30% and with a radiochemical purity of \gt 99%. 4‐[18F]FMP was found to be stable in its radiopharmaceutical formulation, even at high radioactivity concentrations. Additionally, for a comparative study, [18F]FET was synthesized using the same setup in 40% overall yield, with a radiochemical purity \gt 99%. The described automated radiosynthesis allows the production of two different amino acid analogues with minor alternations to the parameter settings of the automated system, rendering this unit versatile for both research and clinical practice. Copyright © 2009 John Wiley & Sons, Ltd. 相似文献